Ankit Mahadevia
2017
In 2017, Ankit Mahadevia earned a total compensation of $3.2M as Chief Executive Officer at Spero Therapeutics, a 291% increase compared to previous year.
Compensation breakdown
| Bonus | $114,000 |
|---|---|
| Option Awards | $2,679,616 |
| Salary | $389,574 |
| Other | $1,087 |
| Total | $3,184,277 |
Mahadevia received $2.7M in option awards, accounting for 84% of the total pay in 2017.
Mahadevia also received $114K in bonus, $389.6K in salary and $1.1K in other compensation.
Rankings
In 2017, Ankit Mahadevia's compensation ranked 3,376th out of 14,666 executives tracked by ExecPay. In other words, Mahadevia earned more than 77.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,376 out of 14,666 | 77th |
Division Manufacturing | 1,158 out of 5,768 | 80th |
Major group Chemicals And Allied Products | 318 out of 2,074 | 85th |
Industry group Drugs | 244 out of 1,730 | 86th |
Industry Pharmaceutical Preparations | 193 out of 1,329 | 86th |
Source: SEC filing on April 27, 2018.
Mahadevia's colleagues
We found three more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2017.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019